Mozhuo Biotech Emerges as a Rising Star in the Single-Cell Sequencing Arena with MobiNova®-100 Platform

Since the publication of Tang Fuchou’s seminal work on single-cell transcriptomics in 2009, single-cell sequencing technology has garnered widespread attention in the fields of scientific research and pharmaceuticals. Single-cell sequencing and its derivative technologies were consecutively named “Breakthrough Technologies of the Year” by Nature and Science in 2018, 2019, and 2020.

On April 15, 2022, at 2:00 PM, MobiDrop held an event for its independently developed single-cell system, MobiNova.^®-100 Online Launch Event. Concurrent with the launch, MobiDrop opened applications for product trials (Follow the MobiDrop official account and reply “Cooperation Registration” in the chat box. Upon approval, you can complete single-cell transcriptome sequencing for 1–4 samples free of charge.Library Construction for Sequencing.）

 MobiNova^®-100 High-Throughput Single-Cell Transcriptomics Solution

MobiDrop was co-founded under the leadership of Professor David Weitz, a pioneer in microfluidic single-cell sequencing technology and an academician of four academies in China and the United States. In 2015, Academician Weitz published Drop-seq and inDrop, high-throughput single-cell sequencing technologies based on droplet microfluidics, paving the way for the widespread application and adoption of high-throughput single-cell technologies.

Dr. Hao Pei, CEO of MobiDrop, and Dr. Wenshan Zheng, CTO, both studied under Professor David Weitz. The newly released MobiNova^®-100 is derived from the latest generation of upgraded droplet microfluidics single-cell technology.

MobiDrop CEO Pei Hao stated that MobiNova^®-100 exhibits extremely high stability, while MobiNova^®-100 to be realizedPrice, Technology, Speedamong the three major breakthroughs. At the press conference, CEO Pei Hao presented extensive test data, showing that MobiNova^®-100 Excellent stability.

The stability of instruments and reagents is the cornerstone of reproducible scientific data, and the stability of single-cell sequencing data has long been a major challenge for researchers. MobiNova^®-100 offers excellent stability and has rapidly gained market recognition. The company’s seven-story GMP-certified production facility and office space in Jiaxing are about to commence operations, enabling rapid mass production of instruments and reagents.

At MobiNova^®-100 Prior to its official market launch, MobiDrop had already engaged in in-depth collaborations with Tsinghua University, Zhejiang University, Huazhong University of Science and Technology, and Tongji University. Major domestic single-cell sequencing service providers, including Novogene, OE Biotech, and Lianchuan Bio, have all shown interest in MobiNova^®-100 was tested.

MobiDrop stated that, in addition to the already released MobiNova^®In addition to the -100 single-cell transcriptome sequencing system, MobiNova®-100 will serve as the foundation for the future development of microbial single-cell sequencing and FFPE sample single-cell sequencing products, which will significantly expand the capabilities of MobiNova.^®-100 applications. Microbial single-cell sequencing and FFPE sample single-cell sequencing are products that have not yet been developed by other platforms but hold broad market prospects.

All three founders of MobiDrop are Harvard University alumni, and the founding team possesses extensive expertise in microfluidic design, microfluidic DNA detection and assay, and microfluidic product development. The company has more than 20 R&D pipelines centered around the MobiNova®-100 system, as well as another product portfolio based on microfluidic technology, MobiGaea^®Digital PCR has entered the medical device approval stage, and its product portfolio can be rapidly adapted for clinical, pharmaceutical, and disease diagnosis applications.

It is reported that MobiDrop secured RMB 150 million in financing in 2021 and is set to receive another round of funding shortly. The company’s R&D team comprises 40% PhD holders, bringing together a multidisciplinary talent pool spanning 15 fields, including mechanical engineering, electronics, optics, firmware, bioinformatics, biochemistry, sequencing, and medicine. Leveraging droplet microfluidics to lead in single-cell analysis and digital PCR (dPCR), and driven by technological innovation and top-tier talent, MobiDrop is rapidly advancing its portfolio of research and in vitro diagnostic (IVD) products.